Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Eosinophilic Esophagitis | 4 | 2022 | 6 | 2.520 |
Why?
|
| Esophagus | 5 | 2018 | 53 | 1.420 |
Why?
|
| Crohn Disease | 3 | 2020 | 113 | 1.210 |
Why?
|
| Proton Pump Inhibitors | 2 | 2022 | 39 | 1.100 |
Why?
|
| Lymphoma, Follicular | 1 | 2020 | 15 | 0.680 |
Why?
|
| Epithelial Cells | 4 | 2018 | 375 | 0.680 |
Why?
|
| Fluticasone | 2 | 2018 | 13 | 0.680 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2018 | 158 | 0.600 |
Why?
|
| Abdominal Abscess | 2 | 2017 | 10 | 0.590 |
Why?
|
| Budesonide | 1 | 2018 | 10 | 0.590 |
Why?
|
| Duodenal Ulcer | 1 | 2016 | 4 | 0.550 |
Why?
|
| Neuroendocrine Tumors | 1 | 2016 | 23 | 0.530 |
Why?
|
| Peanut Hypersensitivity | 1 | 2016 | 4 | 0.530 |
Why?
|
| Desensitization, Immunologic | 1 | 2016 | 9 | 0.530 |
Why?
|
| Glycation End Products, Advanced | 1 | 2016 | 19 | 0.520 |
Why?
|
| Vomiting | 1 | 2016 | 134 | 0.480 |
Why?
|
| Fatty Liver | 1 | 2016 | 97 | 0.480 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2016 | 70 | 0.480 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 404 | 0.480 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 317 | 0.430 |
Why?
|
| Inflammation | 2 | 2018 | 1102 | 0.420 |
Why?
|
| Adolescent | 8 | 2020 | 5930 | 0.410 |
Why?
|
| Tissue Engineering | 3 | 2018 | 133 | 0.370 |
Why?
|
| Esophagitis | 1 | 2009 | 9 | 0.340 |
Why?
|
| Eosinophilia | 1 | 2009 | 28 | 0.330 |
Why?
|
| Eosinophils | 1 | 2009 | 52 | 0.330 |
Why?
|
| Child | 8 | 2020 | 4304 | 0.320 |
Why?
|
| Obesity | 1 | 2016 | 1186 | 0.290 |
Why?
|
| Endoscopy | 3 | 2018 | 97 | 0.290 |
Why?
|
| Child, Preschool | 4 | 2018 | 1839 | 0.280 |
Why?
|
| Administration, Oral | 2 | 2018 | 344 | 0.260 |
Why?
|
| Humans | 14 | 2022 | 59491 | 0.220 |
Why?
|
| Male | 10 | 2020 | 27559 | 0.220 |
Why?
|
| Endoscopy, Digestive System | 2 | 2016 | 30 | 0.220 |
Why?
|
| Biopsy | 2 | 2018 | 375 | 0.210 |
Why?
|
| Infliximab | 2 | 2020 | 55 | 0.190 |
Why?
|
| Retrospective Studies | 5 | 2018 | 6007 | 0.180 |
Why?
|
| Diagnosis, Differential | 2 | 2022 | 900 | 0.180 |
Why?
|
| Methotrexate | 1 | 2020 | 76 | 0.160 |
Why?
|
| Gastroenterology | 1 | 2020 | 53 | 0.160 |
Why?
|
| Esophageal Atresia | 1 | 2018 | 10 | 0.160 |
Why?
|
| Polyurethanes | 1 | 2018 | 30 | 0.150 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 118 | 0.150 |
Why?
|
| 3T3 Cells | 1 | 2018 | 108 | 0.150 |
Why?
|
| Tissue Scaffolds | 2 | 2018 | 80 | 0.150 |
Why?
|
| Treatment Outcome | 3 | 2018 | 5183 | 0.150 |
Why?
|
| Esophagoscopy | 1 | 2018 | 28 | 0.150 |
Why?
|
| Integrins | 1 | 2018 | 108 | 0.150 |
Why?
|
| Administration, Inhalation | 1 | 2018 | 110 | 0.150 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2018 | 179 | 0.140 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 282 | 0.140 |
Why?
|
| Esophageal Diseases | 1 | 2017 | 16 | 0.140 |
Why?
|
| Biomarkers | 1 | 2022 | 1210 | 0.140 |
Why?
|
| Arachis | 1 | 2016 | 5 | 0.130 |
Why?
|
| Drainage | 1 | 2017 | 145 | 0.130 |
Why?
|
| Diet Therapy | 1 | 2016 | 14 | 0.130 |
Why?
|
| Diagnostic Errors | 1 | 2016 | 98 | 0.130 |
Why?
|
| Leptin | 1 | 2016 | 78 | 0.130 |
Why?
|
| Peroxidase | 1 | 2016 | 69 | 0.130 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 305 | 0.120 |
Why?
|
| Stem Cells | 1 | 2017 | 257 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 699 | 0.120 |
Why?
|
| Diet, High-Fat | 1 | 2016 | 160 | 0.120 |
Why?
|
| Weight Gain | 1 | 2016 | 161 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 202 | 0.120 |
Why?
|
| Interleukin-6 | 1 | 2016 | 309 | 0.120 |
Why?
|
| Weight Loss | 1 | 2016 | 260 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 274 | 0.110 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 965 | 0.110 |
Why?
|
| Mice | 2 | 2018 | 10266 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2016 | 283 | 0.110 |
Why?
|
| Urachal Cyst | 1 | 2012 | 2 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2016 | 581 | 0.110 |
Why?
|
| Infant | 1 | 2018 | 1527 | 0.110 |
Why?
|
| Intestinal Fistula | 1 | 2012 | 10 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2020 | 723 | 0.100 |
Why?
|
| Female | 6 | 2018 | 30906 | 0.100 |
Why?
|
| Animals | 4 | 2018 | 19647 | 0.100 |
Why?
|
| Colectomy | 1 | 2012 | 98 | 0.100 |
Why?
|
| Colitis, Ulcerative | 1 | 2012 | 84 | 0.090 |
Why?
|
| Liver | 1 | 2016 | 785 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 724 | 0.090 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2012 | 105 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 302 | 0.090 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2010 | 34 | 0.080 |
Why?
|
| Androstadienes | 1 | 2009 | 30 | 0.080 |
Why?
|
| Clostridium Infections | 1 | 2010 | 46 | 0.080 |
Why?
|
| Community-Acquired Infections | 1 | 2010 | 87 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 1462 | 0.080 |
Why?
|
| Young Adult | 1 | 2018 | 4329 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2012 | 1134 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2017 | 2104 | 0.050 |
Why?
|
| Competency-Based Education | 1 | 2020 | 28 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 93 | 0.040 |
Why?
|
| Incidence | 2 | 2012 | 1237 | 0.040 |
Why?
|
| Swine | 1 | 2018 | 344 | 0.040 |
Why?
|
| Cell Count | 1 | 2017 | 129 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 678 | 0.030 |
Why?
|
| Polyglycolic Acid | 1 | 2015 | 16 | 0.030 |
Why?
|
| Biomimetics | 1 | 2015 | 28 | 0.030 |
Why?
|
| Bioreactors | 1 | 2015 | 34 | 0.030 |
Why?
|
| Polyesters | 1 | 2015 | 47 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2015 | 70 | 0.030 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2015 | 60 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2012 | 1914 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 570 | 0.030 |
Why?
|
| Ileocecal Valve | 1 | 2012 | 1 | 0.030 |
Why?
|
| Ileal Diseases | 1 | 2012 | 5 | 0.030 |
Why?
|
| Calcineurin Inhibitors | 1 | 2012 | 22 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2012 | 37 | 0.030 |
Why?
|
| Purines | 1 | 2012 | 38 | 0.030 |
Why?
|
| Wound Infection | 1 | 2012 | 22 | 0.030 |
Why?
|
| Intestinal Obstruction | 1 | 2012 | 50 | 0.020 |
Why?
|
| Colitis | 1 | 2012 | 76 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 1912 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 2069 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2012 | 153 | 0.020 |
Why?
|
| Metronidazole | 1 | 2010 | 7 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 960 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 127 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2010 | 103 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2012 | 735 | 0.020 |
Why?
|
| Sepsis | 1 | 2012 | 281 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 1281 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 1518 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 873 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 1449 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 2329 | 0.020 |
Why?
|
| Mass Screening | 1 | 2010 | 647 | 0.010 |
Why?
|
| United States | 1 | 2010 | 7510 | 0.010 |
Why?
|